Artystarty
Cantor Fitzgerald initiated coverage of MiMedx Group (NASDAQ:MDXG) with an overweight rating, citing valuation and the wound care product maker’s offerings.
The investment bank said it has a favorable view of the estimated $3.9B advanced wound care and surgical markets. It added that it sees MiMedx’s product portfolio as “differentiated and protected given their strong clinical data,” with the shares attractively valued.
Cantor set its price target for the stock at $11.